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ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a chronic,
progressive, and irreversible fibrotic lung disease
that requires long-term treatment. Given the
importance of adherence to treatment and
management of adverse events (AEs), patients
with IPF need long-term, high-quality support
in living with their condition, and adhering to
therapy so they can derive maximum benefit.
The IPF Care Patient Support Program (IPF Care)
provides support, education, and empowerment
to patients receiving pirfenidone for the
treatment of IPF in Europe, through the
provision of frequent, patient-managed
discussions with specialist IPF nurses. In this
review, we describe the structure of IPF Care in
the United Kingdom (UK) and Austria, two of
the longest-running IPF Care programs to date,
and describe the benefits that these programs
provide to patients with IPF. Analysis of results
demonstrates a low rate of discontinuation
from the program, and provides insight into
the questions and concerns that patients
express, not only with respect to pirfenidone
(the only approved treatment for IPF at the time
of analysis), but also in relation to other aspects
of living with IPF. Pirfenidone dose
modifications are common in patients in IPF
Care and AEs most commonly occur early in
treatment, with the majority of affected
patients continuing on a stable maintenance
dose. This highlights the value of the advice and
support that patients receive in IPF Care
regarding management of AEs and staying on
treatment. Patient satisfaction was high in a
survey of the UK program, with patients
reporting high scores regarding ‘feeling in
control of their condition’, ‘knowing what to
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expect from treatment’, and ‘feeling confident
about how their disease is managed’. IPF Care in
Europe will continue to evolve over time,
striving to provide individually tailored
support and patient-friendly information to
improve treatment outcomes and quality of
life for patients living with IPF.
Keywords: Idiopathic pulmonary fibrosis;
Patient education; Patient support;
Pirfenidone; Respirology
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic,
progressive, irreversible, and fatal lung disease,
with an estimated median survival time of
2–5 years following diagnosis [1–5]. Studies
conducted throughout Europe have estimated
the prevalence of IPF to range between 1–23/
100,000 persons [6–11].
Pirfenidone is an orally active, synthetic
small molecule that inhibits the synthesis of
transforming growth factor b and tumor
necrosis factor-a, both of which have been
demonstrated to play an active role in the
fibrosis observed in IPF [12–17]. Pirfenidone
(Esbriet, InterMune) was the first treatment for
IPF licensed for use in the Europe Union (2011),
followed by Canada (2012), and the United
States (2014) [18]. Pirfenidone has also been
approved for marketing in Norway and Iceland,
and is marketed under different trade names in
China, India, Japan, South Korea, Argentina,
and Mexico [18]. In October 2014, the Food and
Drug Administration approved another agent,
the multi-tyrosine kinase inhibitor, nintedanib
(Ofev, Boehringer Ingelheim), for the
treatment of IPF.
Collective evidence from five double-blind,
randomized, placebo-controlled trials has
shown that pirfenidone slows disease
progression, as measured by lung function and
exercise tolerance [19–22]. Furthermore, a
prespecified pooled analysis of the CAPACITY
(ClinicalTrials.gov #NCT00287729 and
#NCT00287716) and ASCEND
(ClinicalTrials.gov #NCT01366209) studies at
1 year demonstrated that pirfenidone
significantly decreased death from any cause
[hazard ratio (HR) of 0.52 (95% CI 0.31, 0.87)],
and death related to IPF [HR of 0.32 (0.14,
0.76)], versus placebo [20]. Pirfenidone is
generally well tolerated, with gastrointestinal
and skin-related events being the most common
adverse events (AEs). Analyses from pooled
clinical trial data demonstrate that the most
frequently reported AEs experienced with
pirfenidone, versus placebo, were nausea (32%
vs. 12%), rash (26% vs. 8%), diarrhea (20% vs.
14%), fatigue (19% vs. 10%), dyspepsia (16% vs.
5%), anorexia (11% vs. 4%), headache (10% vs.
8%), and photosensitivity reactions (9% vs. 1%)
[23]. However, these events rarely led to
treatment discontinuation during clinical
studies [20, 21].
Critically, these common AEs may first arise
at the initiation of pirfenidone therapy, when
patients are still adjusting to their condition
and treatment plan. Longer term safety findings
from a study in which patients received
pirfenidone for a median duration of 2.6 years
(2,059 person exposure years) are consistent
with the short-term observations [24].
Recommendations for managing, or even
preventing, common AEs have been developed
by a panel of experts in pulmonology,
gastroenterology, and dermatology [25].
Gastrointestinal events can be addressed by
simple measures such as taking pirfenidone
with food (preferably at the end of a meal, or
in split doses throughout a meal), or in some
cases temporary dose reduction/interruption
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with slow re-escalation to the recommended
dose [25, 26]. Skin-related AEs can be prevented
and/or managed primarily by patient behavioral
modification, such as avoiding exposure to
intense sunlight, frequently applying a broad
spectrum, high-protection sunscreen, and using
protective clothing (wide-brimmed hat,
sunglasses, long-sleeve shirt, trousers, gloves)
when outdoors or driving [25].
As with other chronic and progressive
diseases, treatment adherence (defined as the
extent to which a patient acts in accordance
with the prescribed dose and interval of a
treatment regime [27]), is of vital importance
for patients to experience maximum benefit.
Real-world management of adherence and
patient expectation can be variable (from
clinician to clinician and from patient to
patient) compared with standardized clinical
trials, and thus may present particular
challenges for patients with IPF receiving
pirfenidone. For example, patients may face
difficulties in understanding and accepting this
unfamiliar, chronic, irreversible disease [28].
Patients may also struggle with understanding
the importance of adhering to the guidance and
management plan advised by their physicians,
particularly with regard to titrating their dose
(following treatment initiation, pirfenidone is
titrated over a 14-day period to the
recommended dose of nine capsules
(2,403 mg) per day [23]), taking their
medication at the recommended times, and
putting in place the appropriate measures to
prevent and/or manage gastrointestinal and
skin-related AEs. As a result, treatment
persistence with pirfenidone (defined as the
duration of time from initiation to
discontinuation of therapy [27]) may be low.
As such, there was an unmet need for an
initiative that advocates and supports treatment
adherence for patients, from initiation of
pirfenidone therapy through to longer term
exposure. The IPF Care Patient Support Program
(IPF Care) was set up to address this unmet
need. In the remainder of this review, we
describe the structure and objectives of IPF
Care, alongside data that demonstrate the
benefits that the program provides to patients
with IPF. We also report the results of a patient
satisfaction survey of patients in the United
Kingdom (UK) participating in IPF Care. All
patients and physicians who participated in IPF
Care provided informed consent. This article
does not contain any new studies with human
or animal subjects performed by any of the
authors.
THE IPF CARE PATIENT SUPPORT
PROGRAM
IPF Care is a patient support initiative
developed by InterMune in collaboration
with IPF healthcare specialists. To date, the
program has been initiated in a number of
European countries, including Austria, France,
Germany, Italy, the Netherlands, Norway,
Sweden, and the UK. Although the structure
and name of the program may differ from
country to country, all the initiatives share the
same core objectives:
– Establishing a patient support system for
people prescribed pirfenidone as they adjust
to their diagnosis and treatment;
– Providing patient education, support, and
empowerment: teaching patients about the
disease and how they can obtain the most
benefit from pirfenidone treatment;
providing counseling on living with the
condition and on how to adapt their
lifestyle to successfully manage both the
disease and any potential AEs;
Adv Ther (2015) 32:87–107 89
– Providing support and information that
complement the work of the patient’s
specialist healthcare team.
The IPF Care process starts from initial
pirfenidone prescription, and continues
through to comprehensive patient engagement
in the program. Patients have the option to
remain in the program if pirfenidone is
discontinued for any reason. The UK and
Austria have the longest-running IPF Care
programs in Europe to date; as such, the
majority of patients’ experience originates
from these programs. Following prescription of
pirfenidone in the UK or Austria, patients are
informed about IPF Care by their treating
physician. If the patient wishes to be enrolled
in the program, both the patient and physician
provide their written, informed consent.
STRUCTURE OF IPF CARE IN THE UK
AND AUSTRIA
IPF Care in the UK
IPF Care was launched in the UK in May 2013.
The program is managed by Partizan (London,
UK), and led by two specialist IPF nurses (A.
Duck and L. Pigram), who act as IPF Care Health
Coaches to facilitate individually tailored
support to patients through the provision of a
telephone service. Patients are contacted via
telephone by the specialist nurse at mutually
agreed times.
The first call from the nurse is lightly
scripted: the nurse will ask patients how they
are coping with their condition and with
treatment. The nurse will take the opportunity
during this initial contact to ensure that the
patients have understood the instructions from
the physician regarding how and when to take
their pirfenidone dose, and how to up-titrate
during the first few weeks. There will also be
discussion with the patient regarding any
treatment-related AEs they may be
experiencing, and guidance is provided by the
nurse on how the patient can prevent and/or
self-manage these AEs.
Following the initial call, there is a follow-up
call every week or every fortnight for the first
month. Once the patient is established on
therapy, the timing and frequency of
subsequent calls are decided upon by the
nurse and patient together, depending on how
many calls the patient feels he/she would need
(or like) to receive, and how much support and
education the nurse feels is required to help the
individual patient adhere to the treatment plan,
persist with therapy, and adequately manage
the disease. For some patients, this may result in
monthly follow-up calls; others may require
communication less frequently. The IPF nurses
not only have frequent communication with
patients, but can also directly contact treating
physicians regarding individual patients,
particularly with regards to discussion of dose
modification due to emergent AEs and/or
changes in patient circumstances.
In addition to this telephone support
network, patients in the program in the UK
are also provided with patient-tailored
information booklets, including ‘IPF—a guide
for patients’, ‘A guide to your treatment with
Esbriet’, and ‘Introducing IPF Care’. Patients
also receive a ‘My Health Journal’ booklet, that
provides practical tips for living with IPF and
taking pirfenidone, in addition to an
appointment tracker and notes sections to
help patients highlight important points,
capture any concerns or questions they wish
to raise with their healthcare team, and
ultimately self-manage their condition as
required.
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IPF Care in Austria
IPF Care was launched in Austria in April 2013.
At present, all patients are supported by one
dedicated specialist IPF nurse (S. Toescher).
Although similar to the UK program in a
number of ways, one key difference in the
Austrian program is the use of face-to-face
meetings with the nurse in the patient homes
(or other suitable location) throughout the
program. Initially, the nurse contacts the
patient via telephone, to ascertain if the
patient would be open to a home visit, and to
put plans in place to facilitate this meeting,
such as finding suitable dates, and asking if any
other individuals (i.e., family members, friends,
care givers) would like to attend. This initial
telephone conversation is also the first
opportunity for the nurse to assess patient
condition, patient knowledge of IPF, initial
experience and understanding of the
pirfenidone dose titration schedule, and any
concerns about potential AEs. The nurse will
explain that all these topics will be discussed in
greater detail during the initial face-to-face
meeting, and will ask the patient if there are
any other specific topics that they would like to
cover at the meeting, so that adequate
preparation can be made.
The initial face-to-face meeting usually lasts
between 1 and 2 h, and ideally occurs before the
patient has initiated pirfenidone treatment [or
as early as possible after treatment initiation
(within 1–2 weeks)]. In this way, the patients
receive the support and encouragement of the
program from the very beginning of their
pirfenidone experience. This initial meeting
with the patient allows the nurse to assess a
number of important points, including: (1) that
the patient has received adequate information
from the treating physician to understand IPF as
a disease, and how it will potentially affect their
life, and (2) that the patient is aware of how and
when to take pirfenidone, and how to up-titrate
the doses during the first few weeks. The nurse
will also take the opportunity during this initial
face-to-face contact to educate the patient on
the additional measures that can be adopted to
prevent or manage the gastrointestinal and
skin-related AEs (such as splitting the dose,
taking doses during or at the end of a meal, and
using additional sun protection), and to
emphasize the importance of adhering to
these measures so that they can persist with
therapy and experience the maximum benefit
of pirfenidone treatment. The patients will also
be made aware of any additional sources of
information and support that may be available
to them in their community. Vital signs are
monitored and recorded during the initial
meeting, and at all subsequent home visits (if
they occur).
Following the initial face-to-face meeting,
the nurse contacts the patient via telephone
every fortnight for the first month, then every
month for the following 3 months, and
thereafter (if the patient is comfortable with
less frequent communication) every 4–6 weeks,
irrespective of whether the patient is still
receiving pirfenidone. During each telephone
call, the patient is given the option of
additional face-to-face meetings with the
nurse, which can occur every 6–8 weeks if
required. Each patient communication (from
the initial face-to-face meeting to follow-up
telephone calls and/or subsequent home visits)
is individually planned and prepared.
A face-to-face meeting lasts on average 1–2 h,
and a telephone discussion 20–30 min, but may
take longer if there are many issues to discuss, or
if additional family members or friends wish to
take part. After every communication with the
patient, the nurse fills in a ‘visit log’, which
describes what was discussed, including any
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issues with the disease or with treatment, and
any AEs experienced and actions taken to
address them. The patient is encouraged to
bring this visit log to upcoming physician or
hospital appointments. If a patient discontinues
from the program, there are no outbound calls
and no visits organized, unless the patient
requests them. Patients who no longer receive
pirfenidone (for example, those who have
received lung transplants) are still considered
to be in the program and still receive support
from the program, unless they opt out.
As with the UK program, the IPF Care nurse
in Austria has the option (following patient
permission) to contact a treating physician and
discuss dose modification if the patient is
experiencing any treatment-related AEs. In
addition to home visits, Austrian patients also
received an ‘IPF Nurse folder’, which contains
the patient and physician consent forms, a
patient information leaflet and more
information on the program. Furthermore,
once a year, local IPF meetings are arranged in
Austria. At these meetings, patients have the
opportunity to bring along family members and
friends, and meet other patients and IPF
experts. During the first 6 months of 2014,
three IPF Care meetings were held across
different regions of Austria, with a total of 42
participants.
BENEFITS OF IPF CARE
AS OBSERVED IN THE UK
AND AUSTRIAN PROGRAMS
A key element of IPF Care as observed from the
UK and Austrian programs is that calls and/or
visits are open, patient-managed discussions,
with the content and direction of the
conversation dictated by the individual’s
circumstances and needs. This focusses the
communication on topics relevant to the
patient at that specific point in time, and
empowers patients to take control and be the
integral driver in the management of their
disease. The IPF Care nurses in both the UK and
Austria report that patients begin to share their
‘IPF story’ with the nurse from the first initial
telephone contact, posing disease-related
questions regarding etiology and disease
management, speaking about their fears and
anxieties for the future, as well as discussing
more practical aspects such as blood tests and
physician visits. Patients also often volunteer
information regarding their personal
circumstances, hobbies and family support
situation; this information can be valuable to
the nurse in building a solid relationship with
the patient.
IPF Care provides flexibility with regard to
the duration of these conversations, as patients
continue on therapy. The length of follow-up
calls/visits is determined by the patient–nurse
interactions. This allows the nurse the
opportunity to reinforce AE management and
prevention measures and to assess that the
patient has understood the information from
the treating physician regarding titration.
Similarly, the patient has the opportunity to
highlight topics they would like explained or
discussed in greater detail. As all follow-up calls
in IPF Care are patient-led, every call is
individualized. Patients have different
experiences and outlooks, as they continue to
live with and manage this chronic condition.
Some patients are open and positive, telling the
nurse about their family and friends and
describing changes in their own lives (both
disease-related and unrelated) since the last
communication. Other patients may be
looking for the opportunity to talk to a
friendly and understanding confidant about
aspects of their lives and condition, regarding
issues that they say they do not wish to ‘bother’
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their physician or healthcare team about.
Follow-up calls also allow for more practical
discussions, for example about oxygen use,
prevention of AEs and general disease
awareness and management.
A positive aspect that has emerged from the
programs in both the UK and Austria is the role
of the nurse in facilitating and enhancing
communication between the patient and the
treating physician. In this role, the nurse has a
close relationship and frequent communication
with the patient. They are often aware of
situations before the treating physician, and
can therefore inform the healthcare team
directly, or encourage the patient to contact
the physician for advice. For example, during a
regular IPF Care conversation, the patient may
casually mention an upcoming holiday. In such
a case it may be appropriate for the nurse to
directly update the treating physician with this
information. This facilitates appropriate
communication and discussion with the
patient at the next scheduled clinic visit, and
helps the physician to reinforce the need for
extra skincare protection precautions if
outdoors or driving during the vacation, and/
or to be mindful of taking pirfenidone with
food, even if mealtimes or diet are altered
during the time away. Similarly, the nurse can
inform the physician of any concomitant
medications for other conditions that the
patient may be taking (which may have been
prescribed elsewhere) since initiating
pirfenidone. The patient may not always
remember, or think it is necessary, to update
the physician with these details, but the
frequent and open communication that the
nurse has established with the patient facilitates
the exchange of potentially important
information. The nurse can then relay
information to the treating physician to
ensure that they have a more ‘complete
picture’ of the patient, and that they can make
informed decisions regarding treatment and
overall management plan.
A further example of the benefit of this close
patient–nurse–physician relationship relates to
pirfenidone dose titration. During the initial
titration phase, or during a re-titration phase
following temporary dose decrease/
interruption, the close communication with
the patient means that the nurse can inform
and discuss potential management options with
physicians when patients are struggling with
dose titrations and experiencing AEs, which
helps facilitate early physician assessment and
implementation of appropriate measures.
FINDINGS FROM IPF CARE
IN THE UK
Low Rates of Discontinuation
from the Program
As of the end of October 2014 (18 months since
launch), 465 patients had been enrolled in IPF
Care in the UK. The majority of patients (332/
465 patients; 71%) were on pirfenidone therapy
for less than 30 days at the time of enrollment
into the program.
Of the 465 patients enrolled, 71 % (332
patients) remain in the program at the time of
reporting (November 5, 2014). The average time
on treatment for all enrolled patients was
239 days, with an average of 4.1 calls made per
patient. The most common reasons for no
longer participating in the program were
permanent discontinuation of pirfenidone
[n = 74 (16%)] and patient death [n = 51
(11%)]. Eight patients (2%) withdrew from the
program for other reasons. Approximately half
(49%) of all enrolled patients were on
maintenance therapy (i.e., successfully titrated
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to receive a stable pirfenidone dose) at time of
reporting, with smaller proportions of patients
titrating treatment (9%) or temporarily not
receiving treatment (5%), as shown in Fig. 1.
The most common reasons for stopping
treatment and/or withdrawing from the
program (aside from death) were AEs [n = 35
(8%)] and worsening symptoms [n = 12 (3%)],
followed by treatment ‘not working’ [n = 5
(1%)], transplant [n = 3 (\1%)], wrong
diagnosis [n = 1 (\1%)], other health issues
[n = 1 (\1%)], and ‘other’ [n = 20 (4%)], with
no reason specified for some patients [n = 5
(1%)]. Decisions to permanently stop treatment
and/or withdraw from the program were more
often led by the physician [n = 62 (13%)] as
opposed to the patient [n = 15 (3%)] [not
specified: n = 5 (1%)] with most withdrawals
occurring during the second and third months
of therapy [n = 24/82 (29%)], after patients had
participated in, on average, 3.2 calls.
Patients Discuss a Wide Range of Topics,
Not Always Pertaining to Pirfenidone
Treatment
Data have been analyzed to investigate how the
program is performing against its key objectives,
and to ascertain what benefits it is providing for
patients. A total of 823 calls (representing 239
patients) were analyzed. The average initial call
length was 20.4 min and the average follow-up
call length 19.7 min. A list of individual topics
was identified (Table 1), and the frequency with
which these topics were discussed during the
calls was calculated.
Fig. 1 Latest patient status for all patients enrolled in IPF
Care in the UK (N = 465). Maintenance: includes patients
who have successfully titrated to receive a stable pirfenidone
dose. Treatment holiday: includes patients who are
temporarily not receiving pirfenidone. Titrating restart:
includes patients who are starting titration again, after a
break in treatment or following intolerance to the full dose.
Titrating new: includes patients who are continuing with
their ﬁrst titration attempt
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Table 1 Frequency of individual topics discussed during calls in IPF Care in the UK (823 calls assessed)
Individual topics discussed Frequency Higher level topic
Nausea 67 Gastrointestinal





Loss of taste 6
Constipation 5
Rash from sun 30 Skin
Itchiness from sun 12
Redness from sun 8
Flushing/feeling hot 7
Rash (not from sun) 5
Itchiness (not from sun) 5
Redness (not from sun) 0
Elevated LFTs 81 Liver or blood tests




Shortness of breath 80 SOB/cough
Cough 44
Oxygen 132 Non-pirfenidone treatment




Patient reports: deterioration/fear for future if drug ‘does not work’ 47
Going on holiday/vacation 47
Questions on exercise/Is it dangerous to be breathless? 19
Questions on transplant: am I suitable for transplant? What are the criteria
for transplant?
25
Patient expectation of drug 10
Adv Ther (2015) 32:87–107 95
The most frequently discussed topics (total
mentions, all calls) during these conversations
were not directly related to pirfenidone
treatment (Fig. 2a). Patients were more likely
to talk about test results (lung function tests,
chest X-rays, and echocardiograms), oxygen
and homecare/drug delivery (Fig. 2b). Other
illnesses and associated treatments were also
frequently discussed during the calls (Table 1).
Table 1 continued
Individual topics discussed Frequency Higher level topic
Wearing sunscreen 58 Coping strategies
Reduced doses 48
Treatment holidays 45
Antiemetics (maxolon or domperidone) 28
Treatment stopped 27
Taking drug with food 21
Patient stories 20
Patient stops treatment 10
Splitting capsules across meals 8
Patient reduces dose 7
Other illness/medicationsb 159 Otherc
Chest pain or infection 23
Mood/depression/anxiety 22




Patient concerns about drug 3
Difﬁculty in chewing food 2
INR international normalization ratio, LFT liver function tests, SOB shortness of breath
a Topics may be related to IPF, but not speciﬁcally to pirfenidone treatment
b Includes a number of illnesses and associated treatments including renal stones, clots, insect bites, antibiotics, omeprazole,
oramorph, and doxycycline
c Includes individual terms that do not fall into any other identiﬁed higher level topic. May contain a mixture of terms
both related and unrelated to pirfenidone treatment and/or IPF
Fig. 2 Topics discussed during calls in IPF Care in the
UK (823 calls assessed): a most frequently discussed topics
(total mentions, all calls); b non-pirfenidone treatment-
related topics. *Topics may be related to idiopathic
pulmonary ﬁbrosis (IPF), but not speciﬁcally to
pirfenidone treatment; Includes individual terms that do
not fall into any other identiﬁed higher level topic. May
contain a mixture of terms both related and unrelated to
pirfenidone treatment and/or IPF
c
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AEs Occurred Early in Treatment,
But the Majority of Affected Patients
Continued on a Stable Maintenance Dose
of Pirfenidone
In total, 267/823 (32%) calls included a
mention of at least one AE. When analyzed by
each individual communication, patients more
frequently reported AEs from the second call
(which would typically take place 1–2 months
after treatment initiation) onwards (Fig. 3). The
first call will usually take place while the
patients are up-titrating their dose over a
14-day period (minimum). AEs are less likely
to occur during this titration period, but may
start to emerge once patients are receiving the
maximum recommended daily dose of nine
capsules, which would usually coincide with
the timing of the second call. If an AE is
reported during a conversation, a follow-up
call to the patient will be made within
1–2 weeks to check if the self-management
strategies advised by the nurse are effective.
This accounts for the high percentage of
subsequent calls discussing AEs as shown in
Fig. 3. The occurrence of AEs early in treatment
observed here is in agreement with previous
safety assessments of pirfenidone in a clinical
setting, which report that gastrointestinal and
skin-related AEs tend to occur within the first
6 months of treatment and decrease in
frequency over time [24].
When analyzed by number of patients,
140/239 patients (59%) reported at least one
AE during these calls. Of these 140 patients who
reported at least one AE, the majority (66%)
remained on maintenance therapy, with a
smaller proportion (13%) discontinuing
treatment (Fig. 4).
Patient-Reported Satisfaction
with the Program was High
Over the past 20 years, patient satisfaction
surveys have gained increasing acceptance as
sources of information for assessing and
improving healthcare resources [29]. Research
indicates that better ‘patient care experiences’
are associated with higher levels of adherence to
prevention and treatment interventions, better
clinical outcomes, better patient safety within
hospitals, and less healthcare utilization [30]. A
survey assessing patient satisfaction in IPF Care
was performed to ascertain how patients feel
about the program with regard to disease
management and education. Patients
diagnosed with IPF in the previous 12 months,
who were participating in IPF Care for longer
than 4 weeks and who were on maintenance
Fig. 3 Adverse events (AEs) reported in IPF Care in the UK by individual call (823 calls assessed)
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therapy at the last point of contact, were sent a
questionnaire by post consisting of eight
questions related to their experience with the
program (Fig. 5). Of the 100 survey
questionnaires sent to patients, 44 completed
responses were received.
Patient ratings suggested that IPF Care
provided improvements in terms of feeling in
control of their condition, knowing what to
expect from treatment, and feeling confident
about how their disease was managed (Table 2).
The majority of patients also reported that the
topics discussed with the specialist nurses were
‘the same’ or ‘similar’ to the topics discussed at
clinic visits (Fig. 6). However, general feedback
suggested that patients were more comfortable
and relaxed discussing these topics over the
phone with the nurse, as opposed to in a
hospital or clinic environment. When asked to
rate the importance of having specialist nurses
as the IPF Health Coaches (1 = not at all
important; 10 = essential), the average score
was 8.7 (range 1–10; mode 10).
Patients were asked to rate their agreement
with the statement ‘‘I have stayed on Esbriet
treatment longer than I would have done
without the support of the IPF Care program’’
(1 = completely disagree, 10 = completely
agree). The average score reported was 7.0
(range 1–10; mode 10). When asked to rate if
they thought the program would be useful to
other patients taking Esbriet (1 = extremely
unlikely, 10 = definitely), the average score
was 8.7 (range 5–10; mode 10). Patients were
Fig. 4 Latest patient status for all patients who
reported C1 adverse event (N = 140) in IPF Care in the
UK. Maintenance: includes patients who have successfully
titrated to receive a stable pirfenidone dose. Treatment
holiday: includes patients who are temporarily not receiving
pirfenidone. Titrating restart: includes patients who are
starting titration again, after a break in treatment or
following intolerance to the full dose. Titrating new:
includes patients who are continuing with their ﬁrst
titration attempt
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Fig. 5 The IPF Care patient support program survey in the UK
100 Adv Ther (2015) 32:87–107
also asked to provide their reasons for the score
they gave for this last question. Reasons
provided by patients included: ‘‘Knowing
support is a phone call away makes me feel
less panicky’’, ‘‘It provides a human element’’,
‘‘It is helpful to know someone is keeping an eye
on you’’, ‘‘Being able to speak to someone over
the phone about my problems has been very
reassuring, rather than having to wait until my
next clinic visit’’, ‘‘The extra support is
reassuring’’, ‘‘There is always help on the end
of the phone when you are struggling with
breathing’’, ‘‘Gives you more confidence and
peace of mind’’, ‘‘It enables me to discuss all
aspects of IPF and ask questions that may seem
insignificant’’, ‘‘They have changed my life, they
have given me freedom’’, and ‘‘They put my
mind at rest regarding the side effects’’.
At the end of the survey, patients were asked
to provide any other feedback about IPF Care.
The following is a selection of comments: ‘‘Feels
easier to ask trivial things—which are still
important—of a nurse who rings up like a
friend’’, ‘‘Care and support is excellent’’, ‘‘The
IPF nurses are well trained’’, ‘‘I like talking to my
support nurse’’, ‘‘I feel more relaxed talking to
IPF Care support, as hospital environment does
not always help you relax’’, ‘‘With the lack of
knowledge about this disease, any information
is welcome’’, ‘‘Staff are extremely helpful and
have time to talk’’, and ‘‘I feel this is very
important to all patients’’.
It should be noted that as only patients on
maintenance therapy were chosen to participate
in the survey, this may represent a selection
bias. These patients were tolerating the full dose
of pirfenidone with little or no AEs, and may
therefore not have received as many calls from
the IPF Care nurse as patients struggling with
tolerating the full pirfenidone dose.
FINDINGS FROM IPF CARE
IN AUSTRIA
At time of writing, there are currently 69
patients in IPF Care in Austria, which is
Table 2 Patient perception regarding disease, treatment and management before and after participation in IPF Care in the
UK
Statement Parameter Question 1: Before IPF
Care
Question 2: As a result of IPF
Care
I feel in control of my condition Mean 4.5 6.5
Mode 4 8
Range 1–10 2–10
I know what to expect from treatment Mean 5.5 7.7
Mode 5 9
Range 1–10 1–10





Question 1: Thinking back to before you joined the IPF Care program, please rate the following (1 = low; 10 = high)
Question 2: And how would you rate the following now, as a result of the IPF Care program (1 = low; 10 = high)
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estimated to represent approximately 40% of all
patients prescribed pirfenidone in the country.
Dose Modifications are Common in IPF
Care and Enrolled Patients Stay
on Treatment Longer than Patients
Receiving Pirfenidone Outside
of the Program
An 8-month period (November 2013–June
2014) was assessed in which 27 pirfenidone-
treated patients were enrolled in IPF Care (from
November 2013–March 2014) in Austria. Dose
modifications were common in these patients.
Five patients (18.5%) had a prolonged titration
phase, 3 patients (11.1%) a permanent dose
modification, and 3 patients (11.1%) a dose
reduction followed by a subsequent up-titration
to the recommended full dose. These treatment
modifications were decided by the treating
physician, but in close contact with the IPF
Care nurse.
The benefit of the program in Austria with
regard to patients remaining on treatment is
shown in Fig. 7. Almost all 27 patients who
started pirfenidone with the support of the IPF
Care nurse stayed on treatment for at least
3 months. Only 1 out of 27 patients in IPF Care
discontinued treatment during the first
3 months of therapy, compared with a
discontinuation rate of 36% (12/33) in an
unsupported group of patients receiving
pirfenidone outside of the program.
PLACING OUR OBSERVATIONS
IN CONTEXT: FINDINGS FROM
OTHER PATIENT SUPPORT
PROGRAMS
To place our observations in context, and to
support the value of patient education and
empowerment in improving treatment
adherence and patient outcomes, we reviewed
previous publications on patient support
programs, both in IPF and in other chronic
diseases. A small, pirfenidone access program
(operating on the basis of named patient
supply) served as a precursor to IPF Care in the
UK [31]. In this real-world analysis of 40
patients with IPF, six patients (15%)
Fig. 6 Similarity of topics discussed during IPF Care
telephone discussions versus topics discussed during clinic
visits (IPF Care UK survey; N = 37). Two patients did not
answer the question, one patient answered ‘none of the
above’, and four patients provided multiple answers and
were therefore all excluded from analysis
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discontinued during the first 6 months of
treatment. No patients discontinued during
the subsequent 10 months. The authors of the
analysis largely attribute this finding to the
implementation of patient education and
communication measures, including: (1) a
monthly specialist nurse review that occurred
during the first 3 months of treatment to assess
and reinforce AE avoidance measures, and (2)
patients given contact numbers and encouraged
to speak with a specialist nurse if they
experience any AEs. This meant that
appropriate measures (e.g., dose reduction,
temporary dose discontinuation, additional
treatment of AEs) could be advised without
delay to rapidly alleviate AEs.
In Canada, there is a very similar patient
support initiative to IPF Care, called the
INSPIRATION program, managed by
InterMune [32]. An analysis of data from this
program assessed the persistency and adherence
of 308 enrolled patients receiving pirfenidone.
Specialist nurses contacted patients via the
telephone on a weekly (first month), bi-weekly
(next two months) and quarterly (month 4
onwards) basis, with patients self-reporting
their capsule intake. After 6 months of drug
exposure, the persistency rate (patients
remaining on drug) was 81%, with the main
patient-reported reasons for discontinuation
predominantly AEs of gastrointestinal and
skin-related events. The adherence rate
(patients receiving[80% therapeutic dose of
2,403 mg/day) at 6 months was 83%. The
authors of the analysis attribute the high
6-month persistency and adherence rates to
the close nurse–patient follow-up facilitated by
the INSPIRATION program.
Patient support-type programs have also
been implemented in a number of other
chronic illnesses to improve adherence to
medication and disease management, and to
empower self-management skills. Indeed, the
benefits of such a program have been
demonstrated in another debilitating
respiratory disorder: chronic obstructive
pulmonary disease (COPD). Data from 141
patients in a patient-centric COPD program
(that imparted self-management principles, and
provided telephonic nursing outreach and an
action plan for symptom exacerbation) were
compared with data from the same number of
patients who accessed care from their physician
or through emergency departments (control
group) [33]. At 1 year, physician visits were
significantly less frequent for patients in the
program compared with the control group.
Hospital admission, bed days and emergency
Fig. 7 Patients remaining on treatment for C3 months in IPF Care in Austria
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department visits also showed a downward
trend for patients in the program. Another
COPD study assessed the relationship between
self-management abilities, quality of chronic
care delivery, and patient wellbeing of 548
individuals enrolled in a COPD care program
in The Netherlands [34]. A multilevel random-
effects model demonstrated a significant
relationship between quality of chronic care
delivery and the wellbeing of patients.
Interestingly, self-management abilities were
also found to have a significant positive
relationship to patient wellbeing.
One of the largest assessments of disease
management programs described to date comes
from an analysis of data from programs for
asthma (N = 23,793), congestive heart failure
(N = 4,092), and diabetes (N = 29,604), for
patients in the United States Department of
Defense Military Health System (TRICARE) [35].
These voluntary, opt-out, patient-centered
programs provide patients with telephone-
based consultations with a care manager, and
educational materials and newsletters specific to
patient needs. Improvements in patient
outcomes included reduced inpatient days and
medical costs, with increased proportions of
patients receiving appropriate medications and
tests. A survey assessing patient satisfaction
showed that the majority of respondents
(C85%) rated their overall experience as
‘good’, ‘very good’ or ‘excellent’. The majority
of patients (C60%) also ‘agreed’ or ‘strongly
agreed’ that the program has helped them
improve their life, and helped them better
manage different aspects of their disease.
Taken together, these studies of disease
management and patient support programs
across a number of conditions demonstrate
the value of patient education and
empowerment with respect to numerous
endpoints, including treatment adherence and
persistency, patient outcomes, quality of life
and wellbeing, and healthcare utilization and
medical costs. The observations from IPF Care
described in the present article support the
previous findings from other disease
management programs with regard to the
benefit of a patient-centric approach for long-
term, chronic conditions.
CONCLUSIONS
IPF Care in Europe provides individually
tailored support and patient-friendly
information so that patients develop a better
understanding of their chronic condition.
Through close and frequent communication
with specialist nurses, patients receive practical
advice on how to cope with IPF on a daily basis,
and how to manage symptoms, treatment and
AEs over both the short and long term. The
ultimate goal of the program is to improve
treatment outcomes and the overall quality of
life for patients living with IPF.
As observed from IPF Care in the UK and
Austria, in addition to observations from other
disease management initiatives, patient
support programs are of great value in the
management of chronic diseases. IPF Care
complements and enhances healthcare
systems by providing patients with the
opportunity to discuss any issues—not only
relating to pirfenidone, but on any topic
important to them—which can often be
overlooked during formal, clinical
consultations. Observations from the patient
satisfaction survey of patients in IPF Care in
the UK indicate that patients feel positive
about their involvement in the program, that
they believe it to be an important and helpful
outlet, and they feel better educated and more
confident and supported in their disease
management as a result of IPF Care.
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The limitations of the IPF Care data
analysis from the UK and Austrian programs
should be considered when interpreting the
findings. A relatively small number of patients
were included in the analyses, no set study
design or independent evaluation was
implemented for either program, and a
control group of pirfenidone-treated patients
outside IPF Care was not considered in the
analysis of UK data which could potentially
contribute to a biased interpretation of results.
Furthermore, it should be acknowledged that
the additional benefits that IPF Care provides
to patients are variable and dependent on the
level of support already available from their
specialist healthcare team, which for a number
of patients may be sufficient. We believe,
however, that our findings demonstrate that
IPF Care is of added value to patients who
require outside support complementary to
that currently provided by their healthcare
teams.
IPF Care established in countries throughout
Europe will continue to evolve and develop over
time, striving to provide the best possible
support for patients with IPF in the day-to-day
management of this chronic, progressive
disease.
ACKNOWLEDGMENTS
All named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval to the
version to be published. The authors wish to
acknowledge Ro´isı´n O’Connor, inScience
Communications, Springer Healthcare Ltd., for
medical writing and editorial assistance, funded
by InterMune International AG (Muttenz,
Switzerland), and Josh Taylor, Partizan, for
assistance with analysis of the IPF Care UK
data, also funded by InterMune International
AG. Article processing charges were funded by
InterMune International AG.
Conflict of interest. Annette Duck is a part-
time consultant/contractor for Partizan (funded
by InterMune UK and Ireland to run the IPF
Care program in the UK) and has also received
speaker honoraria and support for conference
attendance from InterMune, and advisory board
honoraria from Boehringer Ingelheim. Lucy
Pigram is a part-time consultant/contractor for
Partizan (funded by InterMune UK and Ireland
to run the IPF Care program in the UK). Peter
Errhalt has received speaker honoraria from
InterMune and Boehringer Ingelheim and has
attended advisory boards for InterMune and
Boehringer Ingelheim. Deeba Ahmed is an
employee of InterMune. Nazia Chaudhuri has
received project grants from InterMune UK, has
attended advisory boards for InterMune UK,
and has received support for attendance of
conferences from Boehringer Ingelheim and
InterMune UK.
Compliance with ethics guidelines. All
patients and physicians who participated in
IPF Care provided informed consent. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
Adv Ther (2015) 32:87–107 105
REFERENCES
1. Collard HR, Moore BB, Flaherty KR, et al. Acute
exacerbations of idiopathic pulmonary fibrosis. Am
J Respir Crit Care Med. 2007;176:636–43.
2. Kim DS, Collard HR, King TE Jr. Classification and
natural history of the idiopathic interstitial
pneumonias. Proc Am Thorac Soc. 2006;3:285–92.
3. Ley B, Collard HR, King TE Jr. Clinical course and
prediction of survival in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med.
2011;183:431–40.
4. Meltzer EB, Noble PW. Idiopathic pulmonary
fibrosis. Orphanet J Rare Dis. 2008;3:8.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/
ERS/JRS/ALAT statement: idiopathic pulmonary
fibrosis: evidence-based guidelines for diagnosis
and management. Am J Respir Crit Care Med.
2011;183:788–824.
6. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J,
Tata LJ. Incidence and mortality of idiopathic
pulmonary fibrosis and sarcoidosis in the UK.
Thorax. 2006;61:980–5.
7. Hodgson U, Laitinen T, Tukiainen P. Nationwide
prevalence of sporadic and familial idiopathic
pulmonary fibrosis: evidence of founder effect
among multiplex families in Finland. Thorax.
2002;57:338–42.
8. Karakatsani A, Papakosta D, Rapti A, et al.
Epidemiology of interstitial lung diseases in
Greece. Respir Med. 2009;103:1122–9.
9. Navaratnam V, Fleming KM, West J, et al. The rising
incidence of idiopathic pulmonary fibrosis in the
UK. Thorax. 2011;66:462–7.
10. Thomeer MJ, Costabe U, Rizzato G, Poletti V,
Demedts M. Comparison of registries of interstitial
lung diseases in three European countries. Eur
Respir J Suppl. 2001;32:114s–8s.
11. von Plessen C, Grinde O, Gulsvik A. Incidence and
prevalence of cryptogenic fibrosing alveolitis in a
Norwegian community. Respir Med.
2003;97:428–35.
12. Grattendick KJ, Nakashima JM, Feng L, Giri SN,
Margolin SB. Effects of three anti-TNF-alpha drugs:
etanercept, infliximab and pirfenidone on release of
TNF-alpha in medium and TNF-alpha associated
with the cell in vitro. Int Immunopharmacol.
2008;8:679–87.
13. Liu H, Drew P, Gaugler AC, Cheng Y, Visner GA.
Pirfenidone inhibits lung allograft fibrosis through
L-arginine-arginase pathway. Am J Transplant.
2005;5:1256–63.
14. Nakayama S, Mukae H, Sakamoto N, et al.
Pirfenidone inhibits the expression of HSP47 in
TGF-beta1-stimulated human lung fibroblasts. Life
Sci. 2008;82:210–7.
15. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki
R. Pirfenidone suppresses tumor necrosis factor-
alpha, enhances interleukin-10 and protects mice
from endotoxic shock. Eur J Pharmacol.
2002;446:167–76.
16. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic
action of pirfenidone and prednisolone: different
effects on pulmonary cytokines and growth factors
in bleomycin-induced murine pulmonary fibrosis.
Eur J Pharmacol. 2008;590:400–8.
17. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD,
Kossen K. Antifibrotic activities of pirfenidone
in animal models. Eur Respir Rev.
2011;20:85–97.
18. InterMune (2014) Products–about pirfenidone.
http://www.intermune.com/products. Accessed
Dec 2014.
19. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind,
placebo-controlled trial of pirfenidone in patients
with idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med. 2005;171:1040–7.
20. King TE Jr, Bradford WZ, Castro-Bernardini S, et al.
A phase 3 trial of pirfenidone in patients with
idiopathic pulmonary fibrosis. N Engl J Med.
2014;370:2083–92.
21. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone
in patients with idiopathic pulmonary fibrosis
(CAPACITY): two randomised trials. Lancet.
2011;377:1760–9.
22. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone
in idiopathic pulmonary fibrosis. Eur Respir J.
2010;35:821–9.
23. Esbriet (pirfenidone) (2014) Summary of product




24. Valeyre D, Albera C, Bradford WZ, et al.
Comprehensive assessment of the long-term safety
of pirfenidone in patients with idiopathic
pulmonary fibrosis. Respirology. 2014;19:740–7.
106 Adv Ther (2015) 32:87–107
25. Costabel U, Bendstrup E, Cottin V, et al.
Pirfenidone in idiopathic pulmonary fibrosis:
expert panel discussion on the management of
drug-related adverse events. Adv Ther.
2014;31:375–91.
26. Huang Y, Yap SR, Seiwert SD, Pan L. Nonclinical
studies suggest simple strategies to further improve
the GI tolerability of Pirfenidone. Am J Respir Crit
Care Med. 2014;189(A38):A1420 ATS conference
abstracts.
27. Cramer JA, Roy A, Burrell A, et al. Medication
compliance and persistence: terminology and
definitions. Value Health J Int Soc Pharma
Outcomes Res. 2008;11:44–7.
28. Giot C, Maronati M, Becattelli I, Schoenheit G
(2013) Idiopathic pulmonary fibrosis: an EU patient
perspective survey. Curr Respir Med Rev 9:112–9(8).
29. Al-Abri R, Al-Balushi A. Patient satisfaction survey
as a tool towards quality improvement. Oman Med
J. 2014;29:3–7.
30. Anhang Price R, Elliott MN, Zaslavsky AM, et al.
Examining the role of patient experience surveys in
measuring health care quality. Med Care Res Rev.
2014;71(5):522–54.
31. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C.
Real world experiences: pirfenidone is well
tolerated in patients with idiopathic pulmonary
fibrosis. Respir Med. 2014;108:224–6.
32. MacQuarrie JL, Lebel F. Pirfenidone use in clinical
practice: analysis of data from a Canadian patient
support program for patients with idiopathic
pulmonary fibrosis (INSPIRATION). Am J Respir
Crit Care Med. 2014;189:A1428.
33. Chuang C, Levine SH, Rich J. Enhancing cost-
effective care with a patient-centric chronic
obstructive pulmonary disease program. Popul
Health Manag. 2011;14:133–6.
34. Cramm JM, Nieboer AP. The relationship between
self-management abilities, quality of chronic care
delivery, and wellbeing among patients with
chronic obstructive pulmonary disease in The
Netherlands. Int J Chron Obstruct Pulmon Dis.
2013;8:209–14.
35. Dall TM, Askarinam Wagner RC, Zhang Y, W Yang,
Arday DR, Gantt CJ. Outcomes and lessons learned
from evaluating TRICARE’s disease management
programs. Am J Manag Care. 2010;16:438–46.
Adv Ther (2015) 32:87–107 107
